FDA 2011 process validation guidance: lifecycle compliance model

Area of Science:

• Pharmaceutical Manufacturing and Process Validation
• Quality Systems Engineering
• Regulatory Compliance

Background:

• The pharmaceutical industry is transitioning from document-driven to data-driven compliance.
• The U.S. Food and Drug Administration's 2011 Guidance for Industry on Process Validation emphasizes patient safety through a three-stage lifecycle: design, qualification, and verification.

Purpose of the Study:

• To present a scalable lifecycle compliance model for modernized process validation.
• To support the industry's migration towards a data-driven compliance mindset.
• To reposition the quality system as subordinate to overall system quality.

Main Methods:

• Integration of target product profile, control engineering, and general sum principle techniques.
• Development of a model prioritizing unit operations and significant variables.
• Interpretation of the U.S. Food and Drug Administration's 2011 Guidance for Industry on Process Validation.

Main Results:

• A simplified yet scalable lifecycle compliance model is proposed.
• Documentation requirements are treated as a consequence of the modeling process.
• System quality is defined as the integral of related 'system qualities'.

Conclusions:

• The proposed model facilitates a shift to data-driven process validation.
• This approach enhances the understanding and management of system quality.
• The model provides a structured framework for modernizing validation practices.